Interactions avec télaprévir ou bocéprévir chez des patients greffés hépatiques : à propos de 4 cas cliniques

Charlton, 2011, Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents - A potentially lethal cocktail, Hepatology, 54, 3, 10.1002/hep.24470 Neumann, 2004, Fibrosis progression after liver transplantation in patients with recurrent hepatitis C, J Hepatol, 41, 830, 10.1016/j.jhep.2004.06.029 AFEF, 2011 Thériaque, 2014 Thériaque., 2014 Roche, 2008, Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis, Liver Transpl, 14, 1766, 10.1002/lt.21635 Ghany, 2011, An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases, Hepatology, 54, 1433, 10.1002/hep.24641 Adiwijaya, 2012, A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection, PLoS Comput Biol, 8, e1002339, 10.1371/journal.pcbi.1002339 Bacon, 2011, Boceprevir for previously treated chronic HCV genotype 1 infection, New Engl J Med, 364, 1207, 10.1056/NEJMoa1009482 Muir, 2011, Telaprevir for the treatment of chronic hepatitis C infection, Expert Rev Anti Infect Ther, 9, 1105, 10.1586/eri.11.133 Vispo, 2013, Pharmacokinetics of new oral hepatitis C antiviral drugs, Expert Opin Drug Metab Toxicol, 9, 5, 10.1517/17425255.2013.729577 Cacoub, 2012, Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting anti-virals, J Hepatol, 56, 455, 10.1016/j.jhep.2011.08.006 Berenguer, 2000, Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation, Hepatology, 32, 852, 10.1053/jhep.2000.17924 Leise, 2011, Drug therapy: telaprevir, Hepatology, 54, 1463, 10.1002/hep.24660 Seden, 2011, Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions, Curr Opin HIV AIDS, 6, 514, 10.1097/COH.0b013e32834b54dc Coilly, 2012, Practical management of boceprevir and immunosuppressive therapy in liver transplant recipients with hepatitis C virus recurrence, Antimicrob Agents Chemother, 56, 5728, 10.1128/AAC.01151-12 Burger, 2013, Clinical management of drug-drug interactions in HCV therapy: challenges and solutions, J Hepatol, 58, 792, 10.1016/j.jhep.2012.10.027 Thériaque, 2010 Thériaque, 2011 Kiser, 2012, Review and management of drug interactions with boceprevir and telaprevir, Hepatology, 55, 1620, 10.1002/hep.25653 Garg, 2011, Effect of telaprevir on the pharma-cokinetics of cyclosporine and tacrolimus, Hepatology, 54, 20, 10.1002/hep.24443 Hulskotte, 2012, Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers, Hepatology, 56, 1622, 10.1002/hep.25831 Mantry, 2011, Triple therapy using telaprevir in the treatment of hepatitis C recurrence after liver transplantation: an early single center experience. [abstract 90], Global Antiviral Journal, 7 Kwo, 2012, Use of telaprevir plus peg interferon/ribavirin for null responders post OLT with advanced fibrosis/cholestatic hepatitis C [abstract 202] Werner, 2012, Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data, Liver Transpl, 18, 1464, 10.1002/lt.23542 Glowacki, 2011, Influence of cytochrome P450 3A5 (CYP3A5) genetic polymorphism on the pharmacokinetics of the prolonged-release, once-daily formulation of tacrolimus in stable renal transplant recipients, Clin Pharmacokinet, 50, 451, 10.2165/11587050-000000000-00000 Ghosal, 2011, Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor, Drug Metab Dispos, 39, 510, 10.1124/dmd.110.036996 Shiffman, 2014, Hepatitis C, virus therapy in the direct acting antiviral era, Curr Opin Gastroenterol, 30, 217, 10.1097/MOG.0000000000000062 Thériaque. Monographie Sofosbuvir Solvadi®. Thériaque 2014 http://www.theriaque.org/apps/monographie/index.php?type=SP&id=30299 Consulté le 4 septembre 2014. ANSM-Bristol-Myers Squibb, 2014